vs

Side-by-side financial comparison of Alpine Income Property Trust, Inc. (PINE) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Alpine Income Property Trust, Inc. is the larger business by last-quarter revenue ($18.4M vs $12.5M, roughly 1.5× Avidity Biosciences, Inc.). Alpine Income Property Trust, Inc. runs the higher net margin — 11.9% vs -1398.3%, a 1410.2% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 29.6%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 21.4%).

Alpine Income Property Trust, Inc. is a publicly traded real estate investment trust that owns and operates a diversified portfolio of single-tenant net lease commercial properties across the United States. Its core asset segments include essential retail, industrial, and suburban office spaces, delivering stable recurring rental revenue to support consistent returns for its shareholders.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

PINE vs RNA — Head-to-Head

Bigger by revenue
PINE
PINE
1.5× larger
PINE
$18.4M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+404.5% gap
RNA
434.0%
29.6%
PINE
Higher net margin
PINE
PINE
1410.2% more per $
PINE
11.9%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
21.4%
PINE

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
PINE
PINE
RNA
RNA
Revenue
$18.4M
$12.5M
Net Profit
$2.2M
$-174.4M
Gross Margin
Operating Margin
35.4%
-1513.5%
Net Margin
11.9%
-1398.3%
Revenue YoY
29.6%
434.0%
Net Profit YoY
285.3%
-117.0%
EPS (diluted)
$0.06
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PINE
PINE
RNA
RNA
Q1 26
$18.4M
Q4 25
$16.9M
Q3 25
$14.6M
$12.5M
Q2 25
$14.9M
$3.8M
Q1 25
$14.2M
$1.6M
Q4 24
$13.8M
$3.0M
Q3 24
$13.5M
$2.3M
Q2 24
$12.5M
$2.0M
Net Profit
PINE
PINE
RNA
RNA
Q1 26
$2.2M
Q4 25
$1.5M
Q3 25
$-1.3M
$-174.4M
Q2 25
$-1.6M
$-157.3M
Q1 25
$-1.2M
$-115.8M
Q4 24
$-958.0K
$-102.3M
Q3 24
$3.1M
$-80.4M
Q2 24
$204.0K
$-70.8M
Operating Margin
PINE
PINE
RNA
RNA
Q1 26
35.4%
Q4 25
35.3%
Q3 25
16.6%
-1513.5%
Q2 25
16.8%
-4448.7%
Q1 25
16.0%
-8360.9%
Q4 24
14.3%
-4069.6%
Q3 24
47.9%
-4200.9%
Q2 24
24.0%
-4040.4%
Net Margin
PINE
PINE
RNA
RNA
Q1 26
11.9%
Q4 25
8.7%
Q3 25
-9.0%
-1398.3%
Q2 25
-11.0%
-4089.3%
Q1 25
-8.3%
-7360.0%
Q4 24
-6.9%
-3439.5%
Q3 24
22.8%
-3441.7%
Q2 24
1.6%
-3461.8%
EPS (diluted)
PINE
PINE
RNA
RNA
Q1 26
$0.06
Q4 25
$0.07
Q3 25
$-0.09
$-1.27
Q2 25
$-0.12
$-1.21
Q1 25
$-0.08
$-0.90
Q4 24
$-0.06
$-0.80
Q3 24
$0.21
$-0.65
Q2 24
$0.01
$-0.65

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PINE
PINE
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$2.6M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$312.5M
$1.9B
Total Assets
$745.1M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PINE
PINE
RNA
RNA
Q1 26
$2.6M
Q4 25
$4.6M
Q3 25
$1.2M
$350.2M
Q2 25
$5.0M
$243.9M
Q1 25
$6.1M
$254.2M
Q4 24
$1.6M
$219.9M
Q3 24
$2.6M
$370.2M
Q2 24
$3.3M
$575.8M
Total Debt
PINE
PINE
RNA
RNA
Q1 26
Q4 25
$377.7M
Q3 25
$358.2M
Q2 25
$352.6M
Q1 25
$356.5M
Q4 24
$301.5M
Q3 24
$278.9M
Q2 24
$268.3M
Stockholders' Equity
PINE
PINE
RNA
RNA
Q1 26
$312.5M
Q4 25
$279.9M
Q3 25
$223.5M
$1.9B
Q2 25
$229.8M
$1.2B
Q1 25
$240.9M
$1.3B
Q4 24
$253.0M
$1.4B
Q3 24
$248.2M
$1.5B
Q2 24
$244.0M
$1.2B
Total Assets
PINE
PINE
RNA
RNA
Q1 26
$745.1M
Q4 25
$715.9M
Q3 25
$621.4M
$2.1B
Q2 25
$628.4M
$1.4B
Q1 25
$647.4M
$1.5B
Q4 24
$605.0M
$1.6B
Q3 24
$579.0M
$1.6B
Q2 24
$565.8M
$1.3B
Debt / Equity
PINE
PINE
RNA
RNA
Q1 26
Q4 25
1.35×
Q3 25
1.60×
Q2 25
1.53×
Q1 25
1.48×
Q4 24
1.19×
Q3 24
1.12×
Q2 24
1.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PINE
PINE
RNA
RNA
Operating Cash FlowLast quarter
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PINE
PINE
RNA
RNA
Q1 26
Q4 25
$25.8M
Q3 25
$8.7M
$-156.2M
Q2 25
$9.1M
$-199.7M
Q1 25
$5.8M
$-124.8M
Q4 24
$23.4M
$-99.9M
Q3 24
$6.2M
$-65.6M
Q2 24
$8.0M
$-65.0M
Free Cash Flow
PINE
PINE
RNA
RNA
Q1 26
Q4 25
$-87.8M
Q3 25
$-48.8M
$-156.9M
Q2 25
$-3.0M
$-203.0M
Q1 25
$-55.5M
$-128.6M
Q4 24
$-33.4M
$-103.8M
Q3 24
$-43.0M
$-67.3M
Q2 24
$-13.5M
$-65.5M
FCF Margin
PINE
PINE
RNA
RNA
Q1 26
Q4 25
-519.4%
Q3 25
-334.9%
-1257.6%
Q2 25
-20.0%
-5277.1%
Q1 25
-391.0%
-8174.3%
Q4 24
-242.4%
-3491.0%
Q3 24
-319.3%
-2881.8%
Q2 24
-108.0%
-3204.6%
Capex Intensity
PINE
PINE
RNA
RNA
Q1 26
Q4 25
671.8%
Q3 25
394.8%
5.7%
Q2 25
81.2%
86.9%
Q1 25
432.0%
238.6%
Q4 24
412.3%
131.7%
Q3 24
365.4%
72.9%
Q2 24
172.3%
26.0%
Cash Conversion
PINE
PINE
RNA
RNA
Q1 26
Q4 25
17.48×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
2.02×
Q2 24
39.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PINE
PINE

Lease Income$12.6M68%
Other$5.8M31%
Other Revenue$46.0K0%

RNA
RNA

Segment breakdown not available.

Related Comparisons